Paul Morrissey

Beth Israel Deaconess Medical Center, Boston, MA, USA

Are you Paul Morrissey?

Claim your profile

Publications (8)9 Total impact

  • Article: Altruistic kidney donation to a stranger: psychosocial and functional outcomes at two US transplant centers.
    [show abstract] [hide abstract]
    ABSTRACT: The number of living kidney donors with no preexisting relationship to the recipient has increased sharply. This study compared the psychosocial and functional outcomes of these altruistic donors to a stranger (ADs) with donors with a longstanding relationship with the recipient (traditional donors [TDs]). ADs (n=39) and TDs (n=52), who were similar on age, sex, and year of donation, were recruited from two transplant programs in the United States. Participants completed validated measures of psychosocial and functional outcomes a median of 5 years after donation (range, 1-12 years). ADs and TDs did not differ significantly in the total number of donation motives. Both were motivated by a desire to help, the benefits to the recipient outweighing the risks to the donor, a sense of moral duty, and imagining oneself in the position of the recipient. Psychological benefits were endorsed equally by both types of donors, although TDs reported higher Quid Pro Quo scores relative to ADs (P=0.04). ADs and TDs did not differ significantly on any of the Short Form-36, Version 2 scales (P values ranged from 0.19 to 0.85). Few donors (3 ADs and 1 TD) regretted their donation decision. Overall, findings indicate that carefully screened ADs experience psychosocial and functional outcomes comparable with those of TDs and should not be systematically excluded from the opportunity to donate.
    Transplantation 01/2011; 91(7):772-8. · 4.00 Impact Factor
  • Article: America's multi-tiered healthcare system: is organ transplantation fair?
    Peter Than, Paul Morrissey
    Medicine and health, Rhode Island 12/2009; 92(12):422-3.
  • Article: Intention to treat survival following liver transplantation for hepatocellular carcinoma within a donor service area.
    [show abstract] [hide abstract]
    ABSTRACT: This study aimed to assess the impact of wait times on patient survival following liver transplantation for hepatocellular carcinoma (HCC) in a single donor service area. Patients listed in the New England Organ Bank (NEOB) from 1996 to 2005 for liver transplantation with a diagnosis of HCC were identified from the United Network for Organ Sharing database. The following data were extracted: date of listing, date removed from the wait list, indication for wait list removal, patient death and date of last known follow-up. Kaplan-Meier survival estimates were calculated from the time of listing for transplant (intention to treat liver transplant survival, ITT OLT) and compared to those calculated from the date of transplant (liver transplant, OLT). There were 63 new registrations to the transplant list during the study period. Sixty-one patients were removed from the waiting list: transplanted 41 (65%), death seven (11%), candidate condition deteriorated/too sick to transplant eight (13%), medically unsuitable one (2%), other one (2%), transferred to another center two (3%), and transplanted at another center one (2%). Three-year survival following liver transplantation for primary liver cancer was 85%. When the results were analyzed using an intention to treat analysis there was a 10-20% decrease in survival rate at every time point due to wait list drop-out. Wait list drop-out adversely affects liver transplant survival in transplant centers served by the NEOB. These data should be considered when recommending transplant versus resection as first line therapy for stage I or II HCC in our region.
    HPB 02/2008; 10(6):412-5. · 1.60 Impact Factor
  • Article: Transplantation at Rhode Island Hospital: a decade of commitment.
    Paul Morrissey
    Medicine and health, Rhode Island 04/2007; 90(3):76-7.
  • Article: Solid organ transplation--overview.
    Kevin Tan, Paul Morrissey
    Medicine and health, Rhode Island 04/2007; 90(3):72-5.
  • Article: Logotherapy as an adjunctive treatment for chronic combat-related PTSD: a meaning-based intervention.
    [show abstract] [hide abstract]
    ABSTRACT: Combat-related Post-traumatic Stress Disorder (PTSD) is often highly debilitating and affects nearly all areas of psychosocial functioning. Veterans with PTSD re-experience their traumas in the form of haunting intrusive memories, nightmares and flashbacks, and have chronic difficulty modulating arousal. As a way to cope with these symptoms, many survivors live isolated and avoidant lives, self-medicate with alcohol and substances of abuse, and numb themselves to emotional experiences and relationships with family and friends. Additionally, many combat veterans report survivor guilt, depression, affect dysregulation, and an altered world view in which fate is seen as uncontrollable and life is viewed as devoid of meaning. In this report we describe the use of logotherapy (healing through meaning) for the treatment of combat-related PTSD
    American journal of psychotherapy 02/2006; 60(2):161-74.
  • Article: Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients.
    [show abstract] [hide abstract]
    ABSTRACT: Cytomegalovirus (CMV) is a major pathogen in renal transplant patients causing significant post-transplant morbidity and mortality. Prophylactic antiviral therapy, currently implemented in most kidney transplant centres, has significantly reduced the incidence of CMV infection after transplantation. Oral ganciclovir has been shown to be an effective prophylactic agent in preventing CMV disease and infection with a demonstrated superior efficacy over oral acyclovir. Valacyclovir, a prodrug of acyclovir with a higher level of bioavailability than acyclovir, has also been shown to be effective in preventing CMV disease when given as prophylactic treatment. In a retrospective analysis of 150 renal transplant recipients in our centre, we compared the efficacy of oral ganciclovir with valacyclovir in preventing CMV infection. Seventy-seven consecutive renal transplant recipients prophylactically treated with oral ganciclovir for 12 weeks after transplant were compared with 73 consecutive recipients treated with oral valacylovir for an equal length of time. No difference was noted in the incidence of CMV infection between the two treatment groups (5.1 vs 5.4%) after a 6 month follow-up. Likewise, the incidence of acute rejection was similar in both groups (11.6 vs 6.8%). All cases of CMV infection occurred in high-risk patients (donor positive/recipient negative). The prophylactic use of oral valacylovir is as effective as oral ganciclovir in reducing CMV infection and disease after kidney transplantation.
    Nephrology Dialysis Transplantation 05/2003; 18(4):809-13. · 3.40 Impact Factor
  • Article: Live donor renal transplantation.
    Paul Morrissey, Bette Hopkins-Garcia
    Medicine and health, Rhode Island 05/2002; 85(4):128-30.